The Role of Myeloid Differentiation Factor 2 in Stroke: Mechanisms and Therapeutic Potential

TL;DR

This review explores how Myeloid Differentiation Factor 2 contributes to stroke-related inflammation and brain damage, and its potential as a target for new treatments.

Contribution

The paper highlights MD2 as a novel therapeutic target for stroke by detailing its role in neuroinflammation and neuronal death.

Findings

MD2 plays a key role in mediating inflammatory responses after stroke.

MD2 inhibitors show therapeutic potential in reducing brain damage caused by stroke.

Targeting MD2 could offer new treatment strategies for stroke patients.

Abstract

Stroke represents a significant public health burden, ranking as a leading cause of death and disability globally. The prevalence of stroke increases with age, with ischemic stroke accounting for nearly 87% of cases globally. The pathophysiology of stroke is characterized by neuronal injury, neuroinflammation, and oxidative stress, which exacerbate brain damage and hinder recovery. Myeloid Differentiation Factor 2 (MD2), an accessory protein of Toll-like receptor 4 (TLR4), has emerged as a key player in mediating inflammatory responses in stroke. This short review discusses the molecular mechanisms by which MD2 contributes to neuroinflammation and neuronal death following stroke and highlights MD2 as a promising therapeutic target for stroke treatment. Subsequently, we investigate the potential of MD2 inhibitors, their underlying mechanisms, and the therapeutic prospects of such inhibitors in reducing stroke-induced brain damage.

Figures